Gross Margin: 69.46%
Is the gross margin high or low?
The gross margin of 69.46% is in line with its 5-year average of 68.06%, near the high end of its 5-year range (55.25%–72.54%).
As of Thursday, June 25, 2026. 2.38% below its 12-month average of 71.15%.
PODD Gross Margin
Reported quarterly gross margin; no daily interpolation.
PODD Average Gross Margin Chart
PODD Current vs Average Gross Margin Chart
PODD Gross Margin Metrics
GROSS MARGIN
69.46%
GROSS MARGIN AVG TTM
71.15%
GROSS MARGIN AVG 3Y
69.77%
GROSS MARGIN AVG 5Y
69.22%
GROSS MARGIN AVG 10Y
65.30%
GROSS MARGIN AVG 15Y
58.92%
GROSS MARGIN AVG 20Y
56.78%
CURRENT VS TTM AVG
-2.38%
CURRENT VS 3Y AVG
-0.44%
CURRENT VS 5Y AVG
+0.35%
CURRENT VS 10Y AVG
+6.38%
CURRENT VS 15Y AVG
+17.90%
CURRENT VS 20Y AVG
+22.34%
PODD Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 69.46% | 71.15% | 69.77% | 69.22% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.13% | 18.71% | 19.98% | 20.79% |
| Baxter International Inc. (BAX)vs › | $10.87B | 30.11% | 33.76% | 35.72% | 36.84% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 31.86% | 31.70% | 34.15% | 35.17% |
| Henry Schein, Inc. (HSIC)vs › | $9.38B | 29.69% | 29.43% | 29.32% | 29.12% |
| Revvity, Inc. (RVTY)vs › | $11.78B | 51.44% | 50.55% | 50.58% | 52.43% |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 67.68% | 69.16% | 69.73% | 70.75% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 51.87% | 52.87% | 53.77% | 54.60% |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | 17.39% | 17.24% | 38.82% | 59.22% |
| Solventum Corporation (SOLV)vs › | $13.09B | 53.67% | 54.56% | 56.03% | 57.27% |
Gross Margin Analysis
Gross Margin
69.5%
(Revenue - COGS) / Revenue
Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Gross Margin FAQ
- What is the gross margin for Insulet Corp. (PODD)?
- The gross margin for PODD stock is 69.46%.
- Is Insulet Corp.'s gross margin high or low?
- The gross margin of 69.46% is in line with its 5-year average of 68.06%, near the high end of its 5-year range (55.25%–72.54%).
- What is the TTM average gross margin for Insulet Corp. (PODD)?
- The TTM average gross margin for PODD stock is 71.15%.
- What is the 3Y average gross margin for Insulet Corp. (PODD)?
- The 3Y average gross margin for PODD stock is 69.77%.
- What is the 5Y average gross margin for Insulet Corp. (PODD)?
- The 5Y average gross margin for PODD stock is 69.22%.
- What is the 10Y average gross margin for Insulet Corp. (PODD)?
- The 10Y average gross margin for PODD stock is 65.30%.
- What is the 15Y average gross margin for Insulet Corp. (PODD)?
- The 15Y average gross margin for PODD stock is 58.92%.
- What is the 20Y average gross margin for Insulet Corp. (PODD)?
- The 20Y average gross margin for PODD stock is 56.78%.
PODD Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2026-03-31 | 69.46% |
| 2025-12-31 | 72.54% |
| 2025-09-30 | 72.22% |
| 2025-06-30 | 69.67% |
| 2025-03-31 | 71.88% |
| 2024-12-31 | 72.12% |
| 2024-09-30 | 69.33% |
| 2024-06-30 | 67.74% |
| 2024-03-31 | 69.46% |
| 2023-12-31 | 70.85% |
| 2023-09-30 | 67.78% |
| 2023-06-30 | 66.81% |
| 2023-03-31 | 67.16% |
| 2022-12-31 | 58.78% |
| 2022-09-30 | 55.25% |
| 2022-06-30 | 63.56% |
| 2022-03-31 | 70.99% |
| 2021-12-31 | 69.29% |
| 2021-09-30 | 68.47% |
| 2021-06-30 | 69.41% |
| 2021-03-31 | 66.39% |
| 2020-12-31 | 65.46% |
| 2020-09-30 | 64.87% |
| 2020-06-30 | 62.97% |
| 2020-03-31 | 64.09% |
| 2019-12-31 | 64.04% |
| 2019-09-30 | 64.07% |
| 2019-06-30 | 65.72% |
| 2019-03-31 | 66.87% |
| 2018-12-31 | 66.89% |
| 2018-09-30 | 67.50% |
| 2018-06-30 | 66.05% |
| 2018-03-31 | 61.35% |
| 2017-12-31 | 60.91% |
| 2017-09-30 | 60.46% |
| 2017-06-30 | 58.89% |
| 2017-03-31 | 58.40% |
| 2016-12-31 | 58.83% |
| 2016-09-30 | 58.65% |
| 2016-06-30 | 57.78% |
| 2016-03-31 | 54.24% |
| 2015-12-31 | 45.27% |
| 2015-09-30 | 40.84% |
| 2015-06-30 | 45.48% |
| 2015-03-31 | 53.59% |
| 2014-12-31 | 50.54% |
| 2014-09-30 | 50.73% |
| 2014-06-30 | 49.66% |
| 2014-03-31 | 47.44% |
| 2013-12-31 | 48.18% |
| 2013-09-30 | 44.83% |
| 2013-06-30 | 44.65% |
| 2013-03-31 | 43.86% |
| 2012-12-31 | 43.78% |
| 2012-09-30 | 44.55% |
| 2012-06-30 | 43.76% |
| 2012-03-31 | 42.50% |
| 2011-12-31 | 42.55% |
| 2011-09-30 | 41.62% |
| 2011-06-30 | 45.13% |
| 2011-03-31 | 47.89% |
| 2010-12-31 | 49.79% |
| 2010-09-30 | 45.68% |
| 2010-06-30 | 43.10% |
| 2010-03-31 | 40.30% |
| 2009-12-31 | 36.29% |
| 2009-09-30 | 30.95% |
| 2009-06-30 | 21.68% |
| 2009-03-31 | 16.00% |
| 2008-12-31 | 10.10% |
| 2008-09-30 | -0.86% |
| 2008-06-30 | -31.93% |
| 2008-03-31 | -49.87% |
| 2007-12-31 | -53.15% |
| 2007-09-30 | -100.03% |
| 2007-06-30 | -114.79% |
| 2007-03-31 | -127.69% |
| 2006-12-31 | -140.22% |
| 2006-09-30 | -479.53% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy